Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented ...

Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is ...

Transformational automation accelerates time to results by up to 93.6% for cytogenetics laboratories worldwide ...

A real-world analysis of patients receiving teclistamab prior to 2022 showed comparable outcomes to clinical trials and ...

Bionano Genomics (NASDAQ: BNGO) participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing ...

Get the latest Metropolis Healthcare share price today on NSE & BSE. Explore Metropolis Healthcare stock analysis, financial performance, market capitalization, dividend history, and future outlook ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous ...

Each chromosome pair viewed in a karyotype appears to have its own distinct "bar code" of bands. What changes do scientists look for in a karyotype when diagnosing diseases and disorders? The process ...

A male in his 50s presented with profound leucocytosis, systemic symptoms and marked hepatosplenomegaly. Initial workup with peripheral blood flow cytometry suggested T-cell prolymphocytic leukaemia ...